Orlistat-Acrihin, 120 mg capsules 42 pcs
€40.65 €33.87
Orlistat refers to specific inhibitors of long-acting gastrointestinal lipases. This substance shows its effect in the lumen of the stomach and small intestine by forming a covalent bond with the active serine center of gastric and pancreatic lipases. As a result of the effect of hypolipidemic agent inactivated enzyme loses the ability to break down fats coming with food in the form of triglycerides (TG) to monoglycerides and absorbable free fatty acids.
Since unreplenished TGs are not absorbed from the gastrointestinal tract (GIT), fewer calories are fed into the body and, as a result, body weight is reduced. Thus, the therapeutic effect of the drug is carried out without its absorption into the systemic bloodstream. Due to the activity of orlistat 24-48 hours after oral administration, the concentration of fat in feces increases. By reducing the fat depot, Orlistat provides effective body weight control.
In clinical studies involving obese patients, the group of patients receiving Orlistat showed more pronounced weight loss compared to patients on diet therapy alone. This weight loss was observed within the first 2 weeks of starting Orlistat-Acrychin and continued for 6-12 months even in the presence of a negative response to diet therapy.
Statistically significant significant improvement in the profile of metabolic risk factors associated with obesity was recorded for two years. In addition, there was a significant reduction in body fat deposits when compared to the placebo group.
According to 4-year studies, orlistat therapy was found to significantly reduce the threat of type 2 diabetes, by an average of 37% compared to placebo use. This threat was reduced by about 45% in patients with an initial impairment of glucose tolerance. The group receiving orlistat showed a greater reduction in body weight compared to the placebo group, as well as a significant improvement in the profile of metabolic risk factors. The achieved new body weight level was maintained during all 4 years of the study.
In adolescents with obesity during the 1-year study against the background of orlistat treatment a decrease in body mass index (BMI) as well as a decrease in fat deposits and waist and hip circumference were registered as compared to the placebo group. Also during the period of taking Orlistat-Acrihin a significant decrease in diastolic blood pressure (BP) was observed in adolescents compared to those who received placebo.
Indications
Orlistat-Acrichine is recommended for long-term therapy in obese patients with BMI ⥠30 kg/m² or in overweight patients with BMI ⥠28 kg/m² who have obesity-related risk factors on a moderately restricted low-calorie diet.
Also Orlistat-Acrihin is indicated for administration in patients with diabetes mellitus type 2 with excessive body weight or obesity in combination with moderately restricted hypocaloric diet and/or hypoglycemic drugs (insulin and/or sulfonylurea derivatives, metformin).
.
Active ingredient
Composition
Interaction
Directions for use
Special Instructions
Contraindications
Side effects
Overdose
Similarities
Weight | 0.041 kg |
---|---|
Manufacturer | Polpharma S.A., Poland |
Medication form | capsules |
Brand | Polpharma S.A. |
Other forms…
Related products
Buy Orlistat-Acrihin, 120 mg capsules 42 pcs with delivery to USA, UK, Europe and over 120 other countries.